Electrochromic + Anti-Fog Personal-Protective Eyewear (PPE) Based on Unique, Very Low Power, Conductive Coatings and Leveraging Unique, ANSI Z87.1-/Military-Qualified Electrochromic Eyewear Technology
Electrochromic + Anti-Fog Personal-Protective Eyewear (PPE) Based on Unique, Very Low Power, Conductive Coatings and Leveraging Unique, ANSI Z87.1-/Military-Qualified Electrochromic Eyewear Technology
批准号:
9546419
负责人:
Prasanna Chandrasekhar
金额:
$45.61万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2019-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
With regard to Personal Protective Eyewear (PPE) technologies, a major occupational hazard in high risk
industrial sectors such as manufacturing, mining, construction, warehousing, environmental remediation/-
cleanup and biomedical cleanup (e.g. in Ebola work), but one which has received very limited attention to date,
is that associated with the worker transitioning from very bright to dark areas; fogging of the PPE
exacerbates the situation. Per recent OSHA statistics, the number of fatal accidents potentially caused by
light/dark (L/D) plus fogging issues may be up to 35% of the total (4,383 in 2012, 3.2/100,000 workers), with
non-fatal accidents having a similar proportion. In biohazard work, the suit wearer critically needs automated,
hands-free L/D plus antifogging control. Current PPE technologies for L/D control (e.g. photochromics
changing color with UV light, not working indoors or in cars), clip-on sunshades or extra sunglasses, and for
antifogging (e.g. superhydrophilic coatings or double-pane polycarbonate), are all grossly inadequate. Indeed,
the US Army Public Health Command specifically prohibits photochromics or clip-ons for military personnel.
Now in very recent prior and ongoing work, this firm has developed and patented a new electrochromics
technology, based on unique, matched-dual-polymer Conducting Polymer electrochromics (which change color
with small, e.g. 5 VDC, voltage); this has excellent performance, overcoming drawbacks preventing practical,
commercial electrochromic eyewear heretofore. Typical performance: L/D contrast 1% to 70% (vs. air
reference); thin (< 0.4 mm), flexible, durable construction; unique applied-voltage algorithm residing on an
inexpensive (<$8) Microcontroller yielding switching times of < 2 s LD, ~instantaneous DL; automated-
function (photosensor-based, rechargeable Li battery-powered); very low power (72 h with 12 L/D/L switches
per h before batteries need recharging; 15 µW/cm2, +/- 3.0 VDC); conforming to ANSI Z87.1-2010 and US
military (APEL) specifications. Furthermore, this firm has also developed a unique, active defogging
technology. In the Phase I work, these two technologies (electrochromics + defogging) were combined, with
spectacles/-goggles demonstrated having excellent electrochromic performance, active defogging in < 4
seconds, and very low power consumption. A preliminary CAD design for final-form eyewear was arrived at.
Proposed Phase II work will: (1) Further optimize performance of these spectacles/goggles, including control,
power consumption, defog performance. (2) Demonstrate their function with full-body biomedical suits. (3)
Design and set up a semi-automated, pilot production line for 100 spectacles/-goggles per month, leveraging
the firm’s just-initiated commercial production of its standard (not defogging) electrochromic sunglasses. (4)
Establish commercialization tie-ups with partners identified. If successful, the inexpensive (<$80) product
resulting from this work will be the first commercially viable electrochromics + defogging eyewear, drastically
upgrading PPE. Ancillary markets (skiwear, motor sports, bicycling, football, military) may further lower cost.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于spA-Gel负载Anti-HMGB1原位靶向免疫耐受的猪胰岛类器官移植研
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:程瑶
-
依托单位:
TKIs氘代化修饰通过促进HCC铁死亡增强免疫原性并增敏anti-PD-1治疗的机制研究
-
批准号:JCZRQN202500319
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
肺癌外周血淋巴细胞亚群预测anti-PD1/PDL1疗效的鉴定及应用研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:仇凤启
-
依托单位:
Anti-MDA5阳性皮肌炎病人的NK细胞数量与功能改变在间质性肺疾病中的作用与机制研究
-
批准号:MS25H100014
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:韩咏梅
-
依托单位:
特发性膜性肾病血清标志物anti-PLA2R-IgG4检测方法的建立及临床应用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:徐燕
-
依托单位:
CCL2介导PGK1的O-GlcNAc糖基化修饰诱导CAFs代谢重编程促进头颈癌anti-PD-1免疫治疗耐药的机制研究
-
批准号:
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:苑振楠
-
依托单位:
经 anti-GPC3 修饰的外泌体靶向递送索拉非尼与放疗联合诱
导肝细胞癌铁死亡的研究
-
批准号:2024JJ9608
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:段和新
-
依托单位:
千金藤素通过自噬损伤导致的免疫原性细胞死亡促进 anti-PD1 治疗MSS 型结直肠癌的疗效与机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2024
-
负责人:赵明
-
依托单位:
周细胞 ZEB1/SPP1 旁分泌轴招募 MDSCs 诱导
卵巢癌 anti-PD1/PD-L1 疗法耐药的机制研究
-
批准号:Y24H310009
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:程溥
-
依托单位:
Anti-PD-L1靶向干扰DCs与T细胞动态免疫调控诱发肺癌超进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位: